When analyzed in the functional tumor subgroups, doxorubicin-induced immunoreactivity for p53 (Figure 3A and B) and p21waf1 (Figure 3A and C) almost exclusively segregated with Responder tumors throughout a 24- to 48-h treatment. Here, TP53 is linked to neoplasm.